scholarly journals Case Series of Bifidobacterium longum Bacteremia in Three Preterm Infants on Probiotic Therapy

Neonatology ◽  
2014 ◽  
Vol 107 (1) ◽  
pp. 56-59 ◽  
Author(s):  
Andrea Zbinden ◽  
Reinhard Zbinden ◽  
Christoph Berger ◽  
Romaine Arlettaz
2019 ◽  
Vol 56 (1) ◽  
pp. 163-164 ◽  
Author(s):  
Rossella Iannotta ◽  
Milena Tana ◽  
Francesca Priolo ◽  
Velia Purcaro ◽  
Giovanni Vento ◽  
...  

2008 ◽  
Vol 84 ◽  
pp. S23
Author(s):  
Christ-jan van Ganzewinkel ◽  
Peter Andriessen ◽  
Thilo Mohns ◽  
Richard van Lingen

2011 ◽  
Vol 47 (8) ◽  
pp. 757-762 ◽  
Author(s):  
Marco Piastra ◽  
Daniele De Luca ◽  
Maria Pia De Carolis ◽  
Alessia Tempera ◽  
Eleonora Stival ◽  
...  

2020 ◽  
Vol 10 (01) ◽  
pp. e49-e53
Author(s):  
Ayumi Oshima ◽  
Shun Matsumura ◽  
Ayaka Iwatani ◽  
Machiko Morita ◽  
Sumie Fujinuma ◽  
...  

Abstract Background Although indomethacin and ibuprofen are the standard treatments for hemodynamically significant patent ductus arteriosus (hsPDA), they are associated with renal impairment and gastrointestinal complications. Paracetamol for hsPDA closure does not provoke a peripheral vasoconstrictive effect and seems to have effects similar to those of indomethacin and ibuprofen. We have previously reported the safety of low-dose (7.5 mg/kg) intravenous paracetamol for preterm infants with hsPDA, who were indomethacin-resistant or -contraindicated but did not affect the need for surgical PDA ligation. However, reports considering the use of higher-dose (15 mg/kg) paracetamol for hsPDA have not been published in Japan. Cases In 16 premature infants in whom indomethacin or ibuprofen was contraindicated or ineffective, 15 mg/kg of paracetamol was intravenously administered every 6 hours for 3 days after obtaining parental consent. hsPDA closure or narrowing was observed in 14 infants (88%), with the need for surgical closure totally avoided in nine cases (56%). High plasma paracetamol levels were observed in three cases. No paracetamol-related side effects or adverse events were reported. Conclusion The intravenous administration of higher dose paracetamol was safe and feasible in premature infants with hsPDA. Future clinical trials to explore the optimized dose and timing of administration are needed.


2021 ◽  
Vol 10 (19) ◽  
pp. 4519
Author(s):  
Amy H. Stanford ◽  
Melanie Reyes ◽  
Danielle R. Rios ◽  
Regan E. Giesinger ◽  
Jennifer G. Jetton ◽  
...  

Neonatal hypertension has been increasingly recognized in premature infants with bronchopulmonary dysplasia (BPD); of note, a sub-population of these infants may have impaired left ventricular (LV) diastolic function, warranting timely treatment to minimize long term repercussions. In this case series, enalapril, an angiotensin-converting enzyme (ACE) inhibitor, was started in neonates with systemic hypertension and echocardiography signs of LV diastolic dysfunction. A total of 11 patients were included with birth weight of 785 ± 239 grams and gestational age of 25.3 (24, 26.1) weeks. Blood pressure improvement was noticed within 2 weeks of treatment. Improvement in LV diastolic function indices were observed with a reduction in Isovolumic Relaxation Time (IVRT) from 63.1 ± 7.2 to 50.9 ± 7.4 msec and improvement in the left atrium size indexed to aorta (LA:Ao) from1.73 (1.43, 1.88) to 1.23 (1.07, 1.29). Neonatal systemic hypertension is often underappreciated in ex-preterm infants and may be associated with important maladaptive cardiac changes with long term implications. It is biologically plausible that identifying and treating LV diastolic dysfunction in neonates with systemic hypertension may have a positive modulator effect on cardiovascular health in childhood and beyond.


2012 ◽  
Vol 6 (1) ◽  
Author(s):  
Christ-jan JLM van Ganzewinkel ◽  
Thilo Mohns ◽  
Richard A van Lingen ◽  
Luc JJ Derijks ◽  
Peter Andriessen

Sign in / Sign up

Export Citation Format

Share Document